Pregnancy complications can begin silently, while current approaches often detect risk only after disease develops; MaiRa aims to move intervention earlier by analyzing cell-free RNA in one maternal blood sample at weeks 9–14. The €15m seed round supports clinical validation, commercial rollout and EU/US regulatory work for a platform built on more than 26,000 samples linked to 10,000 PREMOM pregnancies, with planned expansion beyond preeclampsia.